Anti-IgE antibodies

An antibody molecule having a sequence which is substantially identical to the sequence “e26” of FIG. 12 (SEQ ID NOS:

• 15-16).

An antibody molecule comprising an E27 sequence selected from the group consisting of:

• F(ab) fragment, (SEQ ID NOS:
• 19 and 21), sFv fragment (SEQ ID NO:23) or F(ab)′2 [SEQ ID NOS:
• 24 and 26).

An antibody molecule having a sequence which is substantially identical to the sequence “E27” of FIG. 12 (SEQ ID NOS:

• 17-18).

A nucleic acid molecule having a sequence encoding for an E26 antibody fragment selected from the group consisting of:

• F(ab), sFv and F(ab′)2.

A nucleic acid molecule having a sequence substantially identical to one encoding for E26.

16 A nucleic acid molecule having a sequence encoding for an E27 antibody fragment selected from the group consisting of:

• F(ab), sFv and F(ab′)2.

A nucleic acid molecule having a sequence substantially identical to one encoding for E27.

A composition comprising pharmaceutically-acceptable excipient(s) in admixture with an antibody having a sequence substantially similar to “E26” of FIG. 12 (SEQ ID NOS:

• 15-16).

A composition comprising pharmaceutically-acceptable excipient(s) in admixture with an antibody molecule having a sequence substantially similar to “E27” of FIG. 12 (SEQ ID NOS:

• 17-18).

A method of reducing or preventing the IgE mediated production of histamine in a mammal comprising the administration of a therapeutically effective amount of an antibody having a sequence substantially similar to “e26” of FIG. 12 (SEQ ID NOS:

• 15-16).

A method of reducing or preventing the IgE mediated production of histamine in a mammal comprising the administration of a therapeutically effective amount of an E27 antibody having a sequence selected from the group consisting of:

• (SEQ ID NOS:
• 15-16).

A method of reducing or preventing the IgE mediated production of histamine in a mammal comprising the administration of a therapeutically effective amount of an antibody having a sequence substantially similar to “E27” of FIG. 12 (SEQ ID NOS:

• 17-18).

A method of treating a disorder mediated by IgE comprising the administration to a mammal in need thereof a therapeutically effective amount of an antibody having a sequence substantially similar to “E26” of FIG. 12 (SEQ ID NOS:

• 15-16).

A method of treating a disorder mediated by IgE comprising the administration to a mammal in need thereof a therapeutically effective amount of E27 antibody molecule having a sequence fragment selected from the group consisting of:

• (SEQ ID NOS:
• 15-16)

A method of treating a disorder mediated by IgE comprising the administration to a mammal in need thereof a therapeutically effective amount of antibody molecule having a sequence substantially similar to “E27” of FIG. 12 (SEQ ID NOS:

• 17-18).